Previous 10 | Next 10 |
home / stock / adpt / adpt articles
Lisata Therapeutics, Inc.'s (NASDAQ: LSTA) lead pipeline candidate is certepetide (formerly known as LSTA1), which is being developed for treat...
Beam Therapeutics Inc. (NASDAQ: BEAM) is evaluating its leading ex-vivo genome-editing candidate, BEAM-101, in the phase I/II BEACON study for the ...
SEATTLE, July 11, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aim...
On Monday, Cathie Wood-led Ark Invest made a notable investment in Palantir Technologies Inc (NYSE:PLTR), a move that comes as the AI sector gains ...
SEATTLE, May 31, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims...
SEATTLE, May 29, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims...
U.S. stock futures were lower this morning, with the Nasdaq futures declining over 100 points on Friday. Shares of Netflix, Inc. (NASDAQ:NFLX) fell...
Shares of Wang & Lee Group, Inc. (NASDAQ:WLGS) rose sharply in today's pre-market trading after the company reported a year-over-year incr...
SEATTLE, April 17, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that ai...
News, Short Squeeze, Breakout and More Instantly...
Adaptive Biotechnologies Corporation Company Name:
ADPT Stock Symbol:
NASDAQ Market:
Adaptive Biotechnologies Corporation Website:
SEATTLE, July 11, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial...
SEATTLE, May 31, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced that its next-generation sequen...
SEATTLE, May 29, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating ...